ORIGINAL BIOMEDICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.65 TWD | -0.95% |
|
-2.80% | -13.54% |
| Apr. 09 | Original BioMedicals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 107K 3.31K | Sales 2023 | 43K 1.33K | Capitalization | 1.19B 36.73M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -1.24M | Net income 2023 | -59M -1.83M | EV / Sales 2022 | 7,688 x |
| Net cash position 2022 | 29.02M 898K | Net cash position 2023 | 312M 9.67M | EV / Sales 2023 | 20,331 x |
| P/E ratio 2022 |
-21
x | P/E ratio 2023 |
-15
x | Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.94% |
More Fundamentals
* Assessed data
| 1 day | -0.95% | ||
| 1 week | -2.80% | ||
| Current month | +0.97% | ||
| 1 month | -3.10% | ||
| 3 months | -13.54% | ||
| 6 months | -13.54% | ||
| Current year | -13.54% |
1 week
15.40
16.05
1 month
15.2017.15
Current year
14.6028.00
1 year
14.6028.00
3 years
14.6028.00
5 years
14.6028.00
10 years
11.3694.73
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 15.65 | -0.95% | 232,589 |
| 24-05-20 | 15.8 | -1.25% | 204,450 |
| 24-05-17 | 16 | 0.00% | 115,020 |
| 24-05-16 | 16 | -0.93% | 167,199 |
| 24-05-15 | 16.15 | +0.31% | 410,019 |
End-of-day quote Taipei Exchange, May 20, 2024
More quotes
Original BioMedicals Co Ltd is a Taiwan-based company mainly engaged in the development of new drugs with non-new ingredients, and the provision of related research and development services, especially focusing on drugs with new dosage forms, new dosages, new indications and innovative controlled release systems. The Company is engaged in the research and development, design, production and sales of new nanocomposite microcell-based drugs. Products include OBM-B01 for cyanide detoxification and lung protection, OBM-CL for antibiotic infection treatment, radiation injury prevention drug OBM-A01, and OBM-Iron Dextran for improving the formulation and manufacturing process of iron dextran. The Company's products are mainly sold domestically.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.54% | 31.74M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.33% | 21.28B | |
| -5.06% | 18.8B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B |
- Stock Market
- Equities
- 6483 Stock
